Rejuvenate Bio
San Diego, US · Delaware corporation · 5 known investors
Find your way into Rejuvenate Bio
1,277 people in our graph share verified history with the Rejuvenate Bio team — schools, employers, funds. One of them is your warm intro.
Ben Robbinsunlockedknows Daniel Oliver · together at Harvard Business School (overlapped)
×4knows the team · via Harvard Business School
×2knows the team · via MIT
knows the team · via Cedars-Sinai Medical Center
knows the team · via Columbia University Medical Center
knows the team · via Princeton University
Rejuvenate Bio develops gene therapy treatments aimed at the root causes of aging to address chronic, age-related conditions such as osteoarthritis, heart disease, and cancer. It targets both companion animals (particularly dogs) and humans.
Founders & leadership
ND
Noah DavidsohninCSO and cofounderNoah Davidsohn earned a Ph.D. in biological engineering from MIT and a B.S. in Applied Physics from Caltech, with postdoctoral training in George Church's lab at Harvard Medical School focused on genome modification technologies. He is Co-Founder and Chief Scientific Officer of Rejuvenate Bio, which develops gene therapies and epigenetic approaches to treat age-related diseases in both humans and companion animals.
DO
Daniel OliverinCEO and FounderDaniel Oliver is co-founder and CEO of Rejuvenate Bio, a gene therapy company developing treatments for age-related diseases in animals and humans that emerged from work in George Church's lab at Harvard Medical School. He previously co-founded and led Voxel8, a 3D printed electronics company spun out of the Wyss Institute, through product launch and its acquisition by Kornit.
GC
George ChurchCo-Founder and SABGeneral Partner & Investment Committee Member at Kendall Capital Partners
DA
Deborah AscheiminChief Medical OfficerDr. Ascheim is Chief Medical Officer at Rejuvenate Bio, where she leads clinical development strategy and trial execution. She brings three decades of experience in clinical medicine and research, including prior roles as Chief Medical Officer at StrideBio and Capricor Therapeutics, faculty positions in cardiology at Columbia University and Mount Sinai, and leadership of clinical trial units and consulting work focused on gene therapies and complex disease development.
Board
Investors · 5
Reported raises · per SEC filings
Form D private placements$34M disclosed across 2 rounds · 2021–2026
▶$19.5MraisedJun 2026 · 35 investors · BiotechnologyRule 506(b)
▶$19.5MraisedJun 2026 · 35 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Noah DavidsohnExecutive Officer, Director
- David ZhuDirector
- Daniel OliverExecutive Officer, Director
- Offering amount
- $27M
- Amount sold
- $19.5M
- Minimum investment
- $20K
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.6MraisedApr 2021 · 22 investors · BiotechnologyRule 506(b)
▶$14.6MraisedApr 2021 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel OliverExecutive Officer, Director
- Noah DavidsohnExecutive Officer, Director
- Offering amount
- $15.3M
- Amount sold
- $14.6M
- Minimum investment
- $10K
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapLife Biosciences18 shared keywordsLongevity company with diversified therapies to extend healthy human lifespan
Lifespan15 shared keywordsLifespan Research Institute invests in biotechnology startups developing regenerative medicine and longevity therapies. The institute funds companies working on age-related disease treatment, including cellular senescence, tissue damage repair, and cancer therapeutics.
bio12 shared keywordsBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.
Rejuvenation Technologies Inc.10 shared keywordsRejuvenation develops proprietary mRNA and lipid nanoparticle technology to safely lengthen telomeres in human cells, targeting cellular aging and diseases caused by short telomeres including pulmonary fibrosis, liver disease, and bone marrow failure.
Regeneron NASDAQ: REGN www.regeneron.com9 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Companies competing with Rejuvenate Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 8 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of DefenseSpecial Operations Command | Phase II | 2022 | $3M |
| Department of DefenseSpecial Operations Command | Phase IISTTR | 2021 | $2.1M |
| Department of DefenseSpecial Operations Command | Phase II | 2020 | $1.4M |
| Department of DefenseSpecial Operations Command | Phase IISTTR | 2019 | $1.4M |
| Department of DefenseSpecial Operations Command | Phase II | 2018 | $1.4M |
| Department of DefenseSpecial Operations Command | Phase I | 2018 | $150K |
| Department of DefenseSpecial Operations Command | Phase ISTTR | 2018 | $149.9K |
| Department of DefenseSpecial Operations Command | Phase I | 2018 | $99.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Rejuvenate Bio has filed a notice of an exempt offering of securities to raise $27,049,354.00 in New Funding. - intelligence360intelligence360.news · Jul 2026
Rejuvenate Bio Raises $6M in Financingfinsmes.com · Jun 2026Frequently asked questions
- What does Rejuvenate Bio do?
- Rejuvenate Bio develops gene therapy treatments aimed at the root causes of aging to address chronic, age-related conditions such as osteoarthritis, heart disease, and cancer. It targets both companion animals (particularly dogs) and humans.
- Who founded Rejuvenate Bio?
- Rejuvenate Bio was founded by Noah Davidsohn, Daniel Oliver, George Church.
- Who are Rejuvenate Bio's investors?
- Rejuvenate Bio's investors include Companion Fund, Connecticut Innovations, Digitalis Ventures, Kendall Capital Partners, KdT Ventures.
- How much funding has Rejuvenate Bio raised?
- Rejuvenate Bio has disclosed $34M raised across 2 rounds.
- Where is Rejuvenate Bio headquartered?
- Rejuvenate Bio is headquartered in San Diego, US.